8 months ago
INSM
AnalystsNicole GerminoNicole Germino's Stock Forecasts
AnalystsNicole Germino
Sectors:
Industries:
Analyst Ranking
Top 14%
#718 out of 5254 analysts
Average Return
+39.75%
Win Rate
62%16 out of 26
Risk vs Reward
Poor
Good
Nicole Germino's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Insmed IncINSM | +181.92% | $25.27 | $71.24 | 2024-04-23 - 2025-04-22 | Strong Buy |
Insmed IncINSM | +177.52% | $68.32 | $189.60 | 2024-11-01 - 2025-10-31 | Strong Buy |
Insmed IncINSM | +167.81% | $25.10 | $67.22 | 2024-05-16 - 2025-05-15 | Strong Buy |
Perspective Therapeutics IncCATX | +143.33% | $1.80 | $4.38 | 2025-04-07 - 2026-04-06 | Strong Buy |
Y Mabs Therapeutics IncYMAB | +136.54% | $3.64 | $8.61 | 2025-05-14 - 2025-09-15 | Strong Buy |
Nicole Germino Analyst Color
Get additional color on Nicole Germino's coverage of popular stocks
a year ago
INSM
2 years ago
INSM
Nicole Germino's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Insmed IncINSM | 10 | Strong Buy | $139.00 | -3.79% | Maintains | 8 months ago |
Y Mabs Therapeutics IncYMAB | 3 | Strong Buy | $14.00 | +62.60% | Maintains | a year ago |
Perspective Therapeutics IncCATX | 3 | Strong Buy | $8.00 | +90.48% | Maintains | a year ago |
Sangamo Therapeutics IncSGMO | 4 | Strong Buy | $5.00 | N/A | Maintains | a year ago |
Fusion Pharmaceuticals IncFUSN | 3 | Hold | $21.00 | N/A | Downgrades | 2 years ago |
Point Biopharma Global IncPNT | 3 | Hold | $12.50 | N/A | Downgrades | 3 years ago |
Assembly Biosciences IncASMB | 3 | Hold | $24.00 | N/A | Downgrades | 3 years ago |
Forte Biosciences IncFBRX | 1 | Strong Buy | $1,750.00 | N/A | Initiates Coverage On | 6 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.